Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OZOBAX DS vs CYCLOBENZAPRINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Baclofen, a gamma-aminobutyric acid (GABA) analog, acts as an agonist at GABA-B receptors in the spinal cord, leading to decreased excitatory neurotransmitter release and reduced muscle spasticity.
Cyclobenzaprine is a centrally acting muscle relaxant that reduces tonic somatic motor activity at the supraspinal level, primarily at the brainstem reticular formation and descending pathways. It is structurally related to tricyclic antidepressants and inhibits reuptake of norepinephrine and serotonin, but the direct relationship to its muscle relaxant effects is not fully established.
Treatment of spasticity associated with multiple sclerosis,Treatment of spinal cord injury-induced spasticity
Treatment of muscle spasm associated with acute, painful musculoskeletal conditions (FDA approved),Adjunct to rest and physical therapy for relief of muscle spasm (FDA approved)
Adults: 600 mg orally twice daily; if efficacy not achieved after 2–3 weeks, may increase to 600 mg three times daily.
Adults: 5 mg orally three times daily; may increase to 10 mg three times daily based on response. Maximum 30 mg per day.
Terminal elimination half-life is 1.0-1.5 hours in patients with normal renal function; prolonged to 8-12 hours in moderate renal impairment (Cr Cl 30-50 m L/min) and up to 20-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal half-life: 18–24 hours (range 8–37 hours). Clinical context: requires multiple doses to achieve steady state (5–6 days); active metabolite norcyclobenzaprine has half-life ~30 hours.
Hepatic metabolism via deamination; minor CYP450 involvement.
Hepatic metabolism primarily via CYP3A4, CYP1A2, and CYP2D6; also undergoes N-demethylation and glucuronidation. Active metabolites include norcyclobenzaprine.
Renal: 70-80% unchanged; fecal: 20-30%; biliary: <5%
Renal: ~50% as unchanged drug and metabolites; Fecal: ~40% primarily as metabolites; Biliary: minimal.
20-30% bound to serum albumin.
~93% bound to albumin and alpha-1-acid glycoprotein.
0.2-0.3 L/kg; indicates distribution primarily into extracellular fluid.
~5 L/kg (range 3–7 L/kg). Clinical meaning: extensive tissue distribution, including central nervous system.
Oral: 95-100% (well absorbed); intravenous: 100%.
Oral: 33–55% due to first-pass metabolism; lower for immediate-release compared to extended-release (same extent but slower absorption).
e GFR 30–59 m L/min/1.73 m²: 300 mg twice daily. e GFR 15–29 m L/min/1.73 m²: 200 mg twice daily. e GFR <15 m L/min/1.73 m²: 200 mg once daily.
No specific dosing adjustment recommended; use caution in severe renal impairment due to potential accumulation.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: 400 mg per day in divided doses. Child-Pugh Class C: not recommended.
Child-Pugh Class A or B: No adjustment. Child-Pugh Class C: Contraindicated due to risk of toxicity (minimal data). Use with caution in mild to moderate impairment; consider lower starting dose.
Children (6–12 years): 10–15 mg/kg per dose twice daily, max 600 mg daily. Adolescents (12–18 years): same as adult dosing.
Not recommended for children under 15 years; safety and efficacy not established. For adolescents ≥15 years: same as adult dosing.
Start at the lower end of the dosing range (600 mg/day in divided doses) and titrate based on renal function; monitor for side effects.
Start with 5 mg once daily; increase slowly to a maximum of 10 mg three times daily over 2 weeks. Increased sensitivity; monitor for anticholinergic effects and sedation.
Abrupt discontinuation may precipitate withdrawal syndrome, including severe hyperthermia, altered mental status, and muscle rigidity, which can be life-threatening. Taper slowly.
None
Risk of withdrawal syndrome with abrupt cessation,Dose-dependent sedation and dizziness may impair ability to drive or operate machinery,May exacerbate psychiatric disorders; use with caution in patients with depression or schizophrenia,Renal impairment requires dose adjustment,Respiratory depression risk, especially with concomitant CNS depressants
Serotonin syndrome risk, especially with concomitant serotonergic drugs (e.g., SSRIs, SNRIs, MAOIs),Sedation and impairment of motor skills; caution with driving or operating machinery,Anticholinergic effects (e.g., urinary retention, angle-closure glaucoma, constipation),Cardiovascular effects: tachycardia, QT prolongation, arrhythmias (especially in elderly or with pre-existing heart disease),Hepatic impairment: use with caution; reduced clearance in mild impairment, avoid in severe impairment,Withdrawal symptoms after abrupt discontinuation: dysphoria, anxiety, insomnia,Elderly patients: increased risk of falls, confusion, anticholinergic toxicity
Hypersensitivity to baclofen or any component of the formulation,Concurrent use of tricyclic antidepressants may increase risk of respiratory depression
Hypersensitivity to cyclobenzaprine or any component of the formulation,Concomitant use or within 14 days of MAO inhibitors (hypertensive crisis risk),Acute recovery phase after myocardial infarction,Arrhythmias, heart block, or conduction disturbances,Hyperthyroidism,Severe hepatic impairment
No specific food interactions; however, taking with food may reduce gastrointestinal discomfort.
Alcohol should be avoided due to additive CNS depression. Grapefruit juice may increase cyclobenzaprine levels (though data is limited, caution is advised). High-fat meals may delay absorption but not clinically significant. No specific dietary restrictions are required.
Ozobax DS (baclofen) is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, baclofen has been shown to increase the incidence of omphalocele (ventral hernia) in fetuses of rats given approximately 3 times the maximum human dose. In rabbits, an increased incidence of incomplete ossification of sternal centers was observed. Cases of neonatal withdrawal syndrome have been reported with chronic maternal use during the third trimester, presenting as hypertonia, tremor, and seizures. Therefore, use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Avoid use in the first trimester unless clearly needed.
Cyclobenzaprine is classified as FDA Pregnancy Category B. Animal reproduction studies have not shown fetal risk, and there are no adequate and well-controlled studies in pregnant women. Risk cannot be ruled out. First trimester: Limited human data, but no structural anomalies reported. Second trimester: No specific adverse effects documented. Third trimester: Potential for neonatal withdrawal symptoms (e.g., jitteriness, respiratory depression) if used near term.
Baclofen is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.4. The estimated infant dose from breast milk is about 0.1 mg/kg/day, which is less than 1% of the maternal weight-adjusted dose. No adverse effects in nursing infants have been reported. However, caution is advised, especially in premature infants or those with renal impairment. Monitor the infant for sedation, hypotonia, or feeding difficulties.
Cyclobenzaprine is excreted into breast milk in low amounts; the M/P ratio is unknown. Due to its anticholinergic effects, there is potential for adverse effects in the nursing infant (e.g., sedation, constipation). The American Academy of Pediatrics considers it compatible with breastfeeding, but caution is advised; alternatives may be preferred.
During pregnancy, increased plasma volume and enhanced renal clearance may reduce baclofen plasma concentrations, potentially requiring dose adjustments. However, specific pharmacokinetic data in pregnancy are limited. Dosing should be individualized based on clinical response. Monitor for deterioration of symptoms (e.g., increased spasticity) and adjust dose accordingly. If dose increased during pregnancy, reduce gradually postpartum to avoid withdrawal in both mother and neonate.
No specific dose adjustments are recommended during pregnancy. Pharmacokinetic parameters (e.g., clearance) are not significantly altered by pregnancy. Use the lowest effective dose for the shortest duration due to lack of safety data.
OZOBAX DS (baclofen) is a GABA-B receptor agonist used for spasticity. Dosage titration is critical to avoid adverse effects. Abrupt discontinuation can cause withdrawal (hallucinations, seizures). Monitor for respiratory depression, especially in elderly or renal impairment. Consider dose adjustment in renal impairment (Cr Cl <30 m L/min).
Cyclobenzaprine is structurally related to tricyclic antidepressants and shares similar anticholinergic and sedative properties. Onset of action for muscle relaxation is typically 1 hour, but maximal effect may take several days. Avoid use in patients with hyperthyroidism, cardiac disease, or those on MAOIs. Not recommended for use longer than 2-3 weeks due to lack of evidence for chronic use. Caution in elderly due to anticholinergic effects and fall risk.
Take exactly as prescribed; do not stop suddenly.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Avoid alcohol as it may worsen side effects.,Report any signs of withdrawal: confusion, hallucinations, seizures.,Take with food to reduce stomach upset.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Do not drink alcohol or use other CNS depressants (e.g., benzodiazepines, opioids) while taking this medication, as it may increase sedation.,Take this medication exactly as prescribed, usually 3 times a day. Do not take more or less than directed.,This medication is intended for short-term use (up to 2-3 weeks) for muscle spasm. Do not use it for longer without consulting your doctor.,If you experience dry mouth, try sucking on sugar-free candy or ice chips. If you have difficulty urinating or vision changes, contact your doctor.,Do not stop taking this medication abruptly without consulting your doctor, although withdrawal is uncommon with short-term use.
No interactions on record
"The combination of cyclobenzaprine and carbinoxamine results in additive central nervous system depression due to their shared anticholinergic and sedative properties. This can lead to excessive sedation, impaired cognitive and motor function, and increased risk of falls or accidents. Severe cases may result in respiratory depression, especially in elderly patients or those with preexisting conditions."
"Cyclobenzaprine, a centrally acting muscle relaxant with tricyclic antidepressant (TCA)-like structure, and Dezocine, an opioid partial agonist analgesic with mu-opioid receptor activity, both depress the central nervous system (CNS) and have additive serotonergic effects. Concomitant use increases the risk of excessive CNS depression, manifesting as sedation, respiratory depression, and impaired psychomotor function, as well as potential serotonin syndrome due to combined serotonergic activity. Clinically, patients may experience profound drowsiness, confusion, respiratory compromise, and in severe cases, coma or death from respiratory failure."
"Lumacaftor, a potent inducer of cytochrome P450 (CYP) 3A4, significantly reduces the systemic exposure of cyclobenzaprine, a CYP3A4 substrate. This results in decreased plasma concentrations of cyclobenzaprine, potentially leading to reduced therapeutic efficacy for muscle spasm relief. Patients may require dose adjustments or alternative therapies to maintain clinical benefit."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OZOBAX DS vs CYCLOBENZAPRINE HYDROCHLORIDE, answered by our medical review team.
OZOBAX DS is a Skeletal Muscle Relaxant that works by Baclofen, a gamma-aminobutyric acid (GABA) analog, acts as an agonist at GABA-B receptors in the spinal cord, leading to decreased excitatory neurotransmitter release and reduced muscle spasticity.. CYCLOBENZAPRINE HYDROCHLORIDE is a Skeletal Muscle Relaxant that works by Cyclobenzaprine is a centrally acting muscle relaxant that reduces tonic somatic motor activity at the supraspinal level, primarily at the brainstem reticular formation and descending pathways. It is structurally related to tricyclic antidepressants and inhibits reuptake of norepinephrine and serotonin, but the direct relationship to its muscle relaxant effects is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OZOBAX DS and CYCLOBENZAPRINE HYDROCHLORIDE depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OZOBAX DS is: Adults: 600 mg orally twice daily; if efficacy not achieved after 2–3 weeks, may increase to 600 mg three times daily.. The standard adult dose of CYCLOBENZAPRINE HYDROCHLORIDE is: Adults: 5 mg orally three times daily; may increase to 10 mg three times daily based on response. Maximum 30 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OZOBAX DS and CYCLOBENZAPRINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OZOBAX DS is classified as Category C. Ozobax DS (baclofen) is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, baclofen has been shown to i. CYCLOBENZAPRINE HYDROCHLORIDE is classified as Category A/B. Cyclobenzaprine is classified as FDA Pregnancy Category B. Animal reproduction studies have not shown fetal risk, and there are no adequate and well-controlled studies in pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.